Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Examine the Effects of MultiStem in Ischemic Stroke

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Athersys, Inc
Sponsor:
Collaborator:
Medpace, Inc.
Information provided by (Responsible Party):
Athersys, Inc
ClinicalTrials.gov Identifier:
NCT01436487
First received: September 15, 2011
Last updated: November 11, 2014
Last verified: July 2014
  Purpose

A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.


Condition Intervention Phase
Ischemic Stroke
Biological: MultiStem
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke

Further study details as provided by Athersys, Inc:

Primary Outcome Measures:
  • frequency of dose limiting adverse events [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
  • Stroke recovery based on global test analysis including modified Rankin Scale (mRS), NIHSS, and Barthel Index (BI) [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • proportion of subjects with a mRS score of less than or equal to 2 [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • change in functional outcome throughout range of mRS scores [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • changes in outcome measures (mRS, NIHSS, BI) over time [ Time Frame: 365 days ] [ Designated as safety issue: No ]
  • proportion of subjects with an excellent functional outcome [ Time Frame: 90 days ] [ Designated as safety issue: No ]
    • mRS score = 0 to 1; and
    • NIHSS score = 0 to 1; and
    • Barthel Index score = greater than or equal to 95

  • frequency of adverse events [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]
  • change in vital signs [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]
  • change in safety labs [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]
  • frequency of secondary infections [ Time Frame: 365 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 140
Study Start Date: October 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Low dose MultiStem or Placebo
Biological: MultiStem
single infusion 1-2 days following ischemic stroke
Biological: Placebo
single infusion 1-2 days following ischemic stroke
Experimental: Cohort 2
High dose MultiStem or Placebo
Biological: MultiStem
single infusion 1-2 days following ischemic stroke
Biological: Placebo
single infusion 1-2 days following ischemic stroke
Experimental: Cohort 3
Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
Biological: MultiStem
single infusion 1-2 days following ischemic stroke
Biological: Placebo
single infusion 1-2 days following ischemic stroke

  Eligibility

Ages Eligible for Study:   18 Years to 83 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects between 18 and 83 years of age (inclusive)
  • Clinical diagnosis of cortical cerebral ischemic stroke
  • Occurrence of a moderate to moderately severe stroke

Exclusion Criteria:

  • Presence of a lacunar or a brainstem infarct
  • Reduced level of consciousness
  • Major neurological event such as stroke or clinically significant head trauma within 6 months of study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01436487

Contacts
Contact: Medpace Inc (866) 872-2349 recruitment@medpace.com

  Show 34 Study Locations
Sponsors and Collaborators
Athersys, Inc
Medpace, Inc.
Investigators
Study Director: Robert W Mays, PhD Athersys, Inc
  More Information

No publications provided

Responsible Party: Athersys, Inc
ClinicalTrials.gov Identifier: NCT01436487     History of Changes
Other Study ID Numbers: B01-02
Study First Received: September 15, 2011
Last Updated: November 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Athersys, Inc:
ischemic stroke
adult stem cells

Additional relevant MeSH terms:
Cerebral Infarction
Ischemia
Stroke
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014